Pfizer’s Prevnar 20 pneumococcal 20-valent conjugate vaccine has been shown to be safe and effective when given together with the company’s COVID-19 booster shot.

The company launched the combination trial in May 2021, recruiting 570 U.S. adults aged 65 years or older from its pivotal phase 3 COVID-19 vaccine study.

In June 2021, the FDA approved Pfizer’s Prevnar 20 vaccine for preventing invasive disease and pneumonia from 20 different strains of streptococcus.